Olaparib

Generic Name
Olaparib
Brand Names
Lynparza
Drug Type
Small Molecule
Chemical Formula
C24H23FN4O3
CAS Number
763113-22-0
Unique Ingredient Identifier
WOH1JD9AR8
Background

Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...

Indication

Ovarian cancer

Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions
Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

First Posted Date
2023-07-18
Last Posted Date
2023-11-29
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
30
Registration Number
NCT05949424
Locations
🇳🇱

University Medical Center Groningen, Groningen, Netherlands

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Interventions
Drug: XL309 (ISM3091)
Drug: Olaparib
First Posted Date
2023-07-06
Last Posted Date
2024-08-01
Lead Sponsor
Exelixis
Target Recruit Count
377
Registration Number
NCT05932862
Locations
🇺🇸

Exelixis Clinical Site 12, Fountain Valley, California, United States

🇺🇸

Exelixis Clinical Site 8, Orlando, Florida, United States

🇺🇸

Exelixis Clinical Site 10, Kansas City, Missouri, United States

and more 9 locations

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

Phase 1
Recruiting
Conditions
Metastatic Breast Cancer
Interventions
Drug: Olaparib
Drug: 17b-estradiol
First Posted Date
2023-06-13
Last Posted Date
2024-11-21
Lead Sponsor
Mary D Chamberlin
Target Recruit Count
6
Registration Number
NCT05900895
Locations
🇺🇸

Dartmouth Cancer Center, Lebanon, New Hampshire, United States

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

First Posted Date
2023-06-12
Last Posted Date
2024-10-29
Lead Sponsor
Artios Pharma Ltd
Target Recruit Count
260
Registration Number
NCT05898399
Locations
🇺🇸

Jefferson University Hospitals - Kimmel Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

SCRI oncology partners, Nashville, Tennessee, United States

🇺🇸

South Texas Accelerated Research Therapeutics (START) - Midwest, Grand Rapids, Michigan, United States

and more 3 locations

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

First Posted Date
2023-06-05
Last Posted Date
2024-05-06
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
53
Registration Number
NCT05887609
Locations
🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

First Posted Date
2023-05-23
Last Posted Date
2023-05-23
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
24
Registration Number
NCT05870423
Locations
🇳🇱

Erasmus MC, Rotterdam, South Holland, Netherlands

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

First Posted Date
2023-04-11
Last Posted Date
2024-05-02
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT05807126
Locations
🇺🇸

UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States

🇺🇸

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

🇺🇸

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

and more 2 locations

Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors

First Posted Date
2023-01-26
Last Posted Date
2023-03-31
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
115
Registration Number
NCT05700669
Locations
🇺🇸

Next Oncology, San Antonio, Texas, United States

Olaparib Maintenance Therapy in Metastatic Breast Cancer

First Posted Date
2022-11-29
Last Posted Date
2024-01-17
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
300
Registration Number
NCT05629429
Locations
🇨🇳

Taipei Veterans General Hospital, Taipei City, Please Select, Taiwan

🇨🇳

National Taiwan University Hospital Yunlin branch, Yuanlin, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Please Select, Taiwan

Pembro With Radiation With or Without Olaparib

First Posted Date
2022-10-05
Last Posted Date
2024-05-03
Lead Sponsor
Zin W Myint
Target Recruit Count
64
Registration Number
NCT05568550
Locations
🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

🇺🇸

University of Kentucky, Lexington, Kentucky, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy